Acadia Pharma (ACAD) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
August 7, 2015 7:02 AM EDTPiper Jaffray downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Overweight to Neutral with a price target of $48.00 (from $39.00), saying with the Pima' NDA filed the next steps may be more challenging.
Analyst Charles Duncan commented, "ACADIA ended 2Q with $271M in cash,... More
Cowen Raises Price Target on Acadia Pharma (ACAD) Following 2Q15
August 7, 2015 6:56 AM EDTCowen reiterated an Outperform rating on Acadia Pharmaceuticals (NASDAQ: ACAD), and raised the price target to $50.00 (from $43.00), following 2Q15 results. ACAD reported 2Q15 EPS of $(0.39) vs consensus of $(0.33).
Analyst Ritu Baral commented, "ACAD's 2Q15 call was largely uneventful with ACAD... More
